Stone House Investment Management LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Stone House Investment Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 42.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 79 shares of the company’s stock after selling 59 shares during the quarter. Stone House Investment Management LLC’s holdings in Eli Lilly and Company were worth $37,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in LLY. Guyasuta Investment Advisors Inc. grew its position in shares of Eli Lilly and Company by 4.6% in the second quarter. Guyasuta Investment Advisors Inc. now owns 3,024 shares of the company’s stock valued at $1,418,000 after purchasing an additional 132 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Eli Lilly and Company by 4.8% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock worth $28,449,000 after acquiring an additional 3,768 shares during the last quarter. Baystate Wealth Management LLC boosted its position in Eli Lilly and Company by 688.2% during the second quarter. Baystate Wealth Management LLC now owns 3,736 shares of the company’s stock worth $1,752,000 after acquiring an additional 3,262 shares during the last quarter. Simon Quick Advisors LLC boosted its position in Eli Lilly and Company by 13.0% during the second quarter. Simon Quick Advisors LLC now owns 1,874 shares of the company’s stock worth $879,000 after acquiring an additional 215 shares during the last quarter. Finally, Martin Capital Partners LLC acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $234,000. 81.38% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.9 %

Eli Lilly and Company stock traded up $5.51 during trading hours on Monday, hitting $597.22. The company had a trading volume of 1,494,823 shares, compared to its average volume of 3,097,466. The firm has a market capitalization of $566.95 billion, a P/E ratio of 107.54, a price-to-earnings-growth ratio of 3.57 and a beta of 0.33. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. The firm’s fifty day moving average is $577.98 and its 200-day moving average is $509.95. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $629.97.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio (DPR) is 81.88%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on LLY shares. Credit Suisse Group increased their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $673.00 to $722.00 and gave the stock an “overweight” rating in a research note on Friday, November 3rd. Citigroup increased their price target on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the stock an “overweight” rating in a research note on Monday, October 9th. Finally, Barclays raised their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $557.00.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,307 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $555.69, for a total value of $726,286.83. Following the transaction, the insider now directly owns 100,397,503 shares in the company, valued at approximately $55,789,888,442.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,307 shares of the stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $555.69, for a total value of $726,286.83. Following the completion of the sale, the insider now directly owns 100,397,503 shares of the company’s stock, valued at approximately $55,789,888,442.07. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Insiders have sold a total of 535,538 shares of company stock worth $20,881,299,452 in the last 90 days. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.